Results
1
Companies which are more than 50% undervalued based on analyst price target.
1 companies
Lytix Biopharma
Market Cap: NOK 592.1m
A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.
LYTIX
NOK 7.70
7D
-3.8%
1Y
-17.4%